Filter by Category: Antimicrobial Surveillance

Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program.

Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader, presented at ID Week 2018, October 3-7, San Francisco, CA, USA.
#1000

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017)

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#1004

Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. Antimicrob. Agents Chemother.: in press, 2018.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. by Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M and Jain R. published in Infect Drug Resist. 2018; 2018 (11): 1499-1510

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States. Lead author: H Sader, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#107

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS. published in J. Antimicrob. Chemother. 2018; 73 (10) 2748-2756

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). by Sader HS, Castanheira M, Mendes RE and Flamm RK published in J. Antimicrob. Chemother.: in press, 2018.

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-393

Antimicrobial Activity of the Novel Siderophore Cehpalosporin GT-1 Tested Alone and Combined with the β-Lactamase Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clinical Isolates

Antimicrobial Activity of the Novel Siderophore Cehpalosporin GT-1 Tested Alone and Combined with the β-Lactamase Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clinical Isolates. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-571

Antimicrobial Activity of Ceftobiprole When Tested against Gram-Positive Cocci Causing Serious Infections (2016-2017): Endocarditis, Diabetic Foot, and Bone/Joint Infections

Antimicrobial Activity of Ceftobiprole When Tested against Gram-Positive Cocci Causing Serious Infections (2016-2017): Endocarditis, Diabetic Foot, and Bone/Joint Infections. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-581